Dapagliflozin
Dapagliflozin is an SGLT2 inhibitor used in type 2 diabetes, heart failure and selected chronic kidney disease settings. This catalogue includes the single-ingredient tablet Dapasmart.
Key points
- SGLT2 inhibitor: dapagliflozin reduces glucose and sodium reabsorption in the kidney.
- Film-coated tablets are supplied in 5 mg and 10 mg strengths.
- Ketoacidosis can occur without markedly elevated blood glucose.
What dapagliflozin is used for
Dapagliflozin is listed for Type 2 Diabetes Mellitus and Heart Failure. Dapasmart is a single-ingredient tablet line within Diabetes Management, with roles in selected chronic kidney disease settings.
Further reading
Related articles
5 Aug 2026 ⋅ 9 min read
Type 2 Diabetes: Why Early Diagnosis Matters More Than It Sounds
Type 2 diabetes symptoms can be mild enough to go unnoticed for years, so it is often diagnosed after complications have already started. What to watch for, what the treatments do, and why more than half of people with diabetes take no medication for it.
Read guide